# Atrial Natriuretic Peptide (ANP)

Canonical source: https://retacompare.com/encyclopedia/anp

Activates natriuretic peptide receptor A (NPR-A, particulate guanylate cyclase), elevating cGMP to cause vasodilation and natriuresis.

Reference facts

Also known asCarperitide, α-ANP, ANFCategoryCardiovascular & NatriureticMechanism of actionActivates natriuretic peptide receptor A (NPR-A, particulate guanylate cyclase), elevating cGMP to cause vasodilation and natriuresis.TargetsNPR-A (GC-A)Indications under research or approvedAcute decompensated heart failure (Carperitide approved Japan)Regulatory status (reference entry)Not FDA-approved (BNP analog Nesiritide was, but withdrawn 2018)Half-life~3 minutesSequenceSLRRSSCFGGRMDRIGAQSGLGCNSFRYSequence notes28-residue cardiac peptide with disulfide bridge Cys7-Cys23 forming the characteristic 17-residue ring.Molecular weight (Da)3081PDB accession1ANPFirst reported1981
    Primary References

de Bold et al., Life Sci 1981 (ANP discovery)


    Explore research articles about Atrial Natriuretic Peptide (ANP)


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- de Bold et al., Life Sci 1981 (ANP discovery): https://pubmed.ncbi.nlm.nih.gov/7242114/